Novartis Announced The Us Food And Drug Administration (Fda) Granted Approval For Tafinlar (Dabrafenib) + Mekinist (Trametinib) For The Treatment Of Paediatric Patients 1 Year Of Age And Older With Low-Grade Glioma (Lgg) With A Braf V600E Mutation Who Require Systemic Therapy. The Fda Also Approved Liquid Formulations Of Tafinlar And Mekinist, Marking The First Time A Braf/Mek Inhibitor Has Been Developed In A Formulation Suitable For Patients As Young As One Year Of Age. These Approvals Make Tafinlar + Mekinist The First And Only Approved Combination Targeted Therapy To Treat Paediatric Patients With Braf V600E Lgg.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!